GlassScriptPhysician profile
Mary I Mcateer
NPI 1134210578
$1,708.11
in general payments reported to CMS, 2019-2025
24 companies · $472 in 2025
The $472 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2022: $189 · 2023: $100 · 2024: $703 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $575.92 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $203.91 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $114.14 | 2023-2025 | Azstarys |
| Roche Diagnostics Corporation | $89.53 | 2019 | |
| Neos Therapeutics, LP | $82.98 | 2019-2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $78.25 | 2023-2024 | Spravato |
| Noven Therapeutics, LLC | $78.16 | 2023-2025 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $55.65 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $45.29 | 2022-2024 | |
| Owp Pharmaceuticals, INC. | $39.07 | 2022-2024 | Subvenite |
| Novo Nordisk INC | $37.31 | 2019-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $34.55 | 2025 | Austedo Xr |
| Abbvie INC. | $32.36 | 2024 | |
| Tris Pharma INC | $31.23 | 2024-2025 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $26.75 | 2022 | |
| Shire North American Group INC | $23.40 | 2019 | |
| Philips North America LLC | $23.38 | 2019 | |
| Amgen INC. | $17.75 | 2019 | |
| Collegium Pharmaceutical, INC. | $17.28 | 2025 | Jornay Pm |
| Lupin INC. | $13.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.23 | 2019 | |
| Merck Sharp & Dohme LLC | $12.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mcateer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.